SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia (Apr, 10.1056/NEJMe2106315, 2021)

The coronavirus disease 2019 (Covid-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stimulated the development of highly effective vaccines that were produced with unprecedented speed with the use of diverse technologies. No major safety warnings, other than rare cases of anaphylaxis, were reported in the initial trials, which involved tens of thousands of adults, and the risk of serious adverse effects has remained remarkably low after vaccination of more than 400 million people worldwide to date.(1) It is not surprising, however, that new reports of adverse events have emerged as many additional people are vaccinated and follow-up . . .

Automated summary

The Covid-19 pandemic led to the rapid development of highly effective vaccines, with over 400 million people vaccinated so far and a remarkably low risk of serious adverse reactions.